Daily Versus Twice Per Day Tamsulosin for Ureteral Stent Symptoms

Status unconfirmed · Phase 4 · Has a placebo group

Conditions studied: Ureteral Diseases

In brief

A single-center prospective, randomized study to assess two different dosing regimens (0.4 mg QD vs. 0.4 mg BID) of tamsulosin for ureteral stent-related discomfort will be completed.

Key facts

Study ID

NCT03799120

Run by

Gundersen Lutheran Medical Foundation

People needed

80

Starts

2019-02-18

Expected to finish

2021-12-01

Last updated by the study team

2019-02-25

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients between the ages of 18 and 70 years old.
• Planning to undergo ureteroscopy with ureteral stent placement at our site.
• Able to read and understand an English language survey (USSQ).

You may not qualify if…

• Patients who are unable to provide informed consent.
• Patients who are already taking an alpha-blocker.
• Patients with hypersensitivity or known adverse side effects of tamsulosin or its ingredients and those who are not candidates for tamsulosin per attending Urologist discretion.
• Patients with a preexisting bladder condition including UTI within 30 days of the procedure.
• Patients with hepatitis C on boceprevir.
• Patients who have medical conditions known to be associated with chronic pain, those taking medications for chronic pain such as gabapentin or a chronic opioid per the judgement of the PI, or those with a pain contract on file.
• Women who are pregnant or planning to become pregnant.

Where it is running

• Gundersen Health System — La Crosse, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.